TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: First postoperative request for sufentanil analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in LDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in inflammatory cytokines (interleukin 6 and tumour necrosis factor α)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detection of hydronephrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Flank pain
Endpoint domain: Adverse events/effects
Primary endpoint: Bladder pain
Endpoint domain: Adverse events/effects
Primary endpoint: major haemorrhages and ureteric injuries
Endpoint domain: Adverse events/effects
Primary endpoint: pain (visual analogue scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of life (SF-12)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline to endpoint on the HAM-A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder rates based upon clinical global impression-improvement (CGI-I) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean deviation of retinal sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean change in FFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: proportion of values crossing treatment thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Free fatty acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall five-year migration of tibial components
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Overall five-year migration of femoral components
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean 25(OH)D level at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: neuropsychological impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: physical abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NR uptake IC(50) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with care received
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of needs met
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Use of hospital resources
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Quadriceps function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dyspnea scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fatigue scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean postactivity heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Spontaneous myocardial infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: Myocardial infarction with large elevations in troponin or CK-MB fraction
Endpoint domain: Mortality/survival
Primary endpoint: ST-elevation myocardial infarction (STEMI)
Endpoint domain: Mortality/survival
Primary endpoint: Assertiveness
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Social anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Satisfaction with interpersonal communication
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: PTH (Parathyroid Hormone)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: S-CTX (Serum C-terminal telopeptide of type I collagen)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: renal toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: audiologic toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: response to chemotherapy
Endpoint domain: Physiological/clinical
Primary endpoint: Hostility scores on the PANSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: emotional empathy scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recovery of atrial contractility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Classification of FTD from normal aging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Classification of FTD from AD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of respiratory events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lumbar lordosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of Motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cornell scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in immediate symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mania symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: probability of recovery at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for the diagnosis of AMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value for the diagnosis of AMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of stay in the emergency department
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Plasma insulin responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Glycaemic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: IPSS values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for mentholated cigarettes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stability of diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neovascularisation prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric emptying of solids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastric emptying of liquids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: IGF1 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: maternal satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Refractive pattern (M, J0 and J45) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose incremental area under the curve (IAUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cost effectiveness per randomized participant
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Isometric and isokinetic voluntary torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Evoked action potential (M wave) of the vastus lateralis muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Twitch contractile properties of the knee extensors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of patients requesting sedation/analgesia during the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported sexual satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: time to recurrence of bipolar disorder
Endpoint domain: Mortality/survival
Primary endpoint: Bone surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of regenerated bone surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of new bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for analgesia
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Postoperative range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Grade 3/4 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: PH concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in uncorrected distance visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in subjective manifest refraction (spherical equivalent)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induced refractive astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage excess weight loss at 5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OHIP-EDENT-J summary score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 10-point decrement in PSP score
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Relief of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in surface erosions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in log minimal angle resolution visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete epithelization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom free from nocturnal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain following defecation disappeared
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: T-lymphocyte insulin binding and degradation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean total and external sphincter volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction of stress IEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of superficial soft tissue infection
Endpoint domain: Adverse events/effects
Primary endpoint: lung function measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: asthma severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diaphragm thickening fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: navigational abilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cost-related burden
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: better physical functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: greater vitality
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: fewer role limitations because of emotional problems
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Soft tissue injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cord blood 25(OH)D concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MMP‐8 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: hs‐CRP concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Warm threshold increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of maintenance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Recovery profile
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fentanyl consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of emesis
Endpoint domain: Adverse events/effects
Primary endpoint: Whole-body BMD loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Spine BMD loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hip BMD loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Discontinuation of inappropriate medication use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADAS-cog score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improved function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fasting Blood Glucose (BG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean hemoglobin A1c values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean serum AGE-peptide concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 3-year disease-free survival (DFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: end of study liver fat percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percentage of DHA enrichment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in protocol compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased risk of ACM
Endpoint domain: Mortality/survival
Primary endpoint: Time needed for instrumentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End Ra values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tooth substance loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean leg cramp number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean leg cramp duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient ratings of severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: lower glucose iAUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 4-h DIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of daily watery bowel movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Daily stool consistency score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serum TGF-beta1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary albumin excretion (ACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serum amyloid A levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procalcitonin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amputation rates
Endpoint domain: Mortality/survival
Primary endpoint: vascular mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: vein graft stenosis rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: HDL/LDL ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: apoA1 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: NK cell cytotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Circulating NK cell numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tinnitus Handicap Inventory (THI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASQ score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Diagnosis concerning the heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bite force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observer's Assessment of Alertness/Sedation scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurological function scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: decreased sinus symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fewer episodes of acute sinusitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fewer doctor visits for acute illnesses
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Overall infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical resolution at day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiologic resolution at day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in physical activity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Rankin Scale score of 0-2 at 90 days
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Vaccine take
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroconversion (IgA or SNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evidence of RV3-BB replication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: graft flow reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: flow capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement of urinary symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Worsening of urinary incontinence
Endpoint domain: Adverse events/effects
Primary endpoint: Control over eating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total daily energy intake (EI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corrected Near Visual Acuity (CNVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uncorrected Near Visual Acuity (UNVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation rate of eligible women at study enrollment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean total operating time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: RBC sorbitol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adrenaline levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: GFR decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: incidence of serious major bleeding adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Beta cell sensitivity to incretins (SINCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 24-hour point prevalence abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma GLN concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective appraisal of the training experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Actual implementation of activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial volume changes at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to relapse into manic episode
Endpoint domain: Mortality/survival
Primary endpoint: 7-day point-prevalence smoking abstinence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percent IOP reduction from baseline at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder rate (≥15% IOP reduction) at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of preterm labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes